OxThera Announces the Appointment of Dr Alain Munoz to its Board of Directors

Stockholm (ots/PRNewswire) -

OxThera AB, a Stockholm-based privately-held biopharmaceutical
company with a product in late stage clinical development focusing
on Primary hyperoxaluria (PH), announces the appointment of Dr Alain
Munoz to its board of directors.

"It is my pleasure to welcome Alain to the board of Oxthera," said
Dr. Georges Gemayel, Chairman of Oxthera. "His deep industry
experience and successful track record of clinical development and
business leadership over his career will be of important value to
Oxthera in its development of Oxabact for treating Primary
hyperoxaluria."

"I am honored to join Oxthera," says Alain Munoz. "I believe the
company is poised to make a real difference in patients suffering
from this devastating rare disease. I am excited to share my insights
with the OxThera Board and its management team to help the company
deliver on the promise of this new therapy."

Alain has an MD in Cardiology and Anesthesiology and was the head
of the Cardiology department at the University Hospital of
Montpellier-Nimes. Alain has numerous publications and has been a
member of the scientific committee of the French Drug Agency. Alain
has over 25 years' experience in the pharmaceutical industry as a
senior executive within the Sanofi Group and with Fournier
Laboratories. He has an in-depth knowledge of the EU, US and Japanese
regulatory process and markets. Under his leadership numerous NDA's
were obtained world-wide (Adenocard®, Plavix®, Lipanthyl®/Tricor(TM),
Esclim®, Ikervis®) Alain is Chairman of the Strategic Board of
Hybrigenics (ALHYG.PA), a board member of Valneva SE (VLA), a board
member of Zealand Pharma (ZEAL),and adviser to KURMA Biofund.

OxThera is developing a novel treatment, Oxabact, for Primary
hyperoxaluria (PH), a fatal disease in children, and where there are
currently no available therapies. The company recently initiated a
pivotal Phase III study in PH with Oxabact in order to stop and/or
delay disease progression. Oxabact is an oral product, composed of
highly concentrated freeze-dried live bacteria (Oxalobacter
formigenes). This commensal bacteria promotes the enteric elimination
of oxalate, thereby reducing the oxalate burden in the kidneys.

PH is a rare autosomal recessive disorder leading to markedly
elevated levels of endogenous oxalate causing kidney deterioration
and a gradual calcification of soft tissues. If left untreated, the
disease can cause kidney failure and premature death. Currently, the
sole available cure is a combined transplantation of liver and
kidneys.

Oxabact holds orphan drug designations in the EU and the US for
the treatment of PH, and in EU for treatment of Short Bowel Syndrome
(SBS).

http://www.oxthera.com

About OxThera

OxThera holds worldwide rights for compositions and methods of use
for treatment of hyperoxaluria for two products; Oxabact and Oxazyme.
Oxthera has a strong international investor consortium including
LSP, Kurma, Industrifonden, Sunstone, Ysios and Fleurie Investments.

ots Originaltext: OxThera AB
Im Internet recherchierbar: http://www.presseportal.de

Contact:
//www.oxthera.com

Original-Content von: OxThera AB, übermittelt durch news aktuell